Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 2/20 | 0.64 |
| ▸ | NPC1 | O15118 | 1/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 3/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL5158699 | 0.82 | NPC1 (0.62) | ATMNPC1RAB9ALMNAL3MBTL1 | |
| Hydrochloric Acid SCHEMBL6131224 | 0.82 | NPC1 (0.65) | ATMNPC1RAB9ALMNATSHR | |
| Hydrochloric Acid SCHEMBL31173710 | 0.82 | NPC1 (0.65) | ATMNPC1RAB9ALMNATSHR | |
| SCHEMBL741714 | 0.81 | NPC1 (0.62) | ATMNPC1RAB9ALMNATSHR | |
| Hydrochloric Acid SCHEMBL10444520 | 0.79 | NPC1 (0.61) | ATMNPC1RAB9ALMNATSHR | |
| Hydrochloric Acid SCHEMBL5345941 | 0.79 | NPC1 (0.58) | ATMNPC1RAB9ALMNATSHR | |
| Hydrochloric Acid SCHEMBL29550623 | 0.79 | NPC1 (0.58) | ATMNPC1RAB9ALMNATSHR | |
| Hydrochloric Acid SCHEMBL4553569 | 0.79 | NPC1 (0.62) | ATMNPC1RAB9AALDH1A1POLB | |
| SCHEMBL23630256 | 0.78 | NPC1 (0.57) | ATMNPC1RAB9ALMNATSHR | |
| Hydrochloric Acid SCHEMBL22345164 | 0.78 | RAB9A (1.00) | ATMNPC1RAB9ATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4134364-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2025-07-30 | — | — | EP | disclosed |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-06-06 | — | — | US | disclosed |
| US-11884680-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2024-01-30 | — | — | US | disclosed |
| EP-4134364-A2 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2023-02-15 | — | — | EP | disclosed |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2022-10-06 | — | — | US | disclosed |
| EP-3640241-B1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2022-09-28 | — | — | EP | disclosed |
| CN-108558889-B | Bromodomain inhibitors | 赛尔基因昆蒂赛尔研究公司 | 2021-11-05 | — | — | CN | disclosed |
| US-10941160-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. (US) | 2020-05-14 | — | — | US | disclosed |
| EP-3640241-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2020-04-22 | — | — | EP | disclosed |
| EP-3290407-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc (US) | 2018-03-07 | — | — | EP | disclosed |
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RES INC (US) | 2017-06-08 | — | — | US | disclosed |
| US-9598372-B2 | Bromodomain inhibitors | CELGENE QUANTICEL RESEARCH, INC. (US) | 2017-03-21 | — | — | US | disclosed |
| EP-3057586-A1 | BROMODOMAIN INHIBITORS | Celgene Quanticel Research, Inc. (US) | 2016-08-24 | — | — | EP | disclosed |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2016-04-28 | — | — | US | disclosed |
| US-9115114-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-07-02 | — | — | US | disclosed |
| US-9034900-B2 | Bromodomain inhibitors | Quanticel Pharmaceuticals, Inc. (US) | 2015-05-19 | — | — | US | disclosed |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | CELGENE QUANTICEL RESEARCH, INC. | 2015-04-23 | — | — | US | disclosed |
| WO-2015058160-A1 | BROMODOMAIN INHIBITORS | Quanticel Pharmaceuticals, Inc. (US) | 2015-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170158709-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-20240182490-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-20220315601-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-20150111885-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-10941160-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-20150183784-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-20200148703-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-11884680-B2 | Bromodomain inhibitors | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
| US-20160115134-A1 | BROMODOMAIN INHIBITORS | BRD3, EP300, BRPF3 | ACHE 4439/4885ATM 858/4885NPC1 2992/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.